Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05780151
Other study ID # EU-CT number 2022-500449-26-00
Secondary ID 1006010
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date July 10, 2023
Est. completion date November 2025

Study information

Verified date June 2024
Source UMC Utrecht
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo®.


Description:

The proposed study has been designed to compare the scientific and operational quality of fully decentralised and hybrid approaches to a conventional clinical trial approach and evaluate the feasibility of such approaches. The primary study objectives are to (1) assess potential benefits of a DCT approach on participant recruitment, retention, diversity, site and participant satisfaction, and cost and (2) to determine acceptability of a DCT approach by measuring variables related to safety oversight, treatment adherence and data quality (missing data and query rate) within the arms that have a different degree of decentralisation. The secondary study objective is to determine whether the efficacy of treatment with Toujeo® (insulin glargine 300 U/mL) is within the accepted range within the arms with different degree of decentralisation. The design is a parallel-group, open-label, multi-centre study in Europe for patients with Type 2 diabetes mellitus ( T2DM) with glycated haemoglobin (HbA1c) between 7% and 10% and treated with basal insulin as part of their glucose-lowering treatment. The study consists of 2 parts with 3 different arms. Part A has site-based recruitment followed by a 1:1 randomization into a conventional arm and a hybrid arm. Part B has decentralised recruitment, no randomization and consists of a fully remote arm. The study will enrol approximately 150 adults in each site-based arm (conventional and hybrid) and approximately 300 in the remote arm, for a total of 600 participants in approximately 5-6 countries. Both Part A and Part B will consist of a screening period (3-6 weeks), a treatment period with open-label Toujeo® (24 weeks) and a follow-up period (2-4 days after end of treatment [EOT]).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 107
Est. completion date November 2025
Est. primary completion date November 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: 1. Participant with T2DM diagnosed for at least 1 year before the screening visit (V1). 2. Participant treated with a stable basal insulin regimen (i.e. type of insulin and time/frequency of the injection), for at least 3 months before the screening visit. 3. The total daily basal insulin dose should be stable (±20%) for at least 1 month before the screening visit. 4. Participant treated with =1 noninsulin antidiabetic drugs at stable dose in the 3 months before the screening visit. 5. Signed written informed consent or e-consent depending on the arm. 6. Participant's mental and physical status allows them to be able to perform their activities of daily living with no or minimal assistance, including the ability to administer injectable insulin and measure their blood glycaemic level. 7. Willing and able to permit home visits (only for Part A of the study). 8. Willing and able to comply with study drug receipt, accountability, and return processes and procedures. 9. Access to tablet/smartphone with Bluetooth functionality. 10. Access to internet connection that allows remote data entry and, for part B, video conferencing. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: 1. Age <18 years. 2. HbA1c at screening visit: <7.0% or >10.0%. 3. Patient not willing to self-manage insulin titration algorithm. 4. Type 1 diabetes mellitus. 5. Treatment with mixed insulin (premixes), short-acting insulin, fast acting insulin analogues or Toujeo® during the 3 months before the screening visit. 6. Use of systemic glucocorticoids (excluding topical application or inhaled forms) for two weeks or more within 8 weeks prior to the time of screening. 7. Any clinically significant abnormality identified at the time of screening, or any condition (including known substance or alcohol abuse, or psychiatric disorder) that in the opinion of the Investigator or any sub-Investigator would make implementation of the protocol or interpretation of the study results difficult or would preclude the safe participation of the participant in this study. 8. Use of any investigational drug within 1 month or 5 half-lives, whichever is longer, prior to screening visit. 9. Participant is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol. 10. Participant whom the investigator deems otherwise ineligible (e.g. unable to understand and follow instructions). Reason for ineligibility will be documented. 11. Pregnant or breastfeeding woman at the time of screening. 12. Woman of childbearing potential not protected by acceptable method(s) of birth control and/or who are unwilling or unable to be tested for pregnancy (see Section 10.3). 13. Known hypersensitivity / intolerance to insulin glargine or any of Toujeo® excipients. 14. Participant who withdraws consent during the screening (participant who is not willing to continue or fails to return). 15. Despite screening of the participant, enrolment is stopped at the study level.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Methodological intervention
All three arms will receive the same clinical intervention but will differ in their level of decentralisation, the methodological intervention.
Drug:
Toujeo
All participants in the study will receive Toujeo® (insulin glargine 300 U/mL). During the treatment period, Toujeo® injection will be administered once daily at the same time as the participant's previous basal insulin was injected, for participant previously treated with once daily injection. In case of previous insulin treatment administered twice a day, the time of injection of Toujeo® will have to be agreed between the physician and the participant before first administration.

Locations

Country Name City State
Denmark Steno Diabetes Centre Odense Odense
Denmark Syddansk Universitet Odense
Germany Studienzentrum Diabetespraxis Dr. Braun Berlin
Germany Klinische Forschung Dresden GmbH Dresden
Germany Velocity Clinical Research Leipzig GmbH Leipzig
United Kingdom FutureMeds Soho Health Centre Birmingham
United Kingdom Blackpool Teaching Hospitals NHS Foundation Trust Blackpool
United Kingdom University Hospitals Leicester NHS Trust Leicester
United Kingdom NIHR Patient Recruitment Centre Newcastle, The Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle

Sponsors (4)

Lead Sponsor Collaborator
Mira Zuidgeest IMI Trials@Home consortium, Innovative Medicines Initiative, Sanofi

Countries where clinical trial is conducted

Denmark,  Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Enrolment rates Time to enrolment from Site activation until last participant enrolled 32 weeks
Primary Retention rates Proportion of participants completing the study period 6 months
Primary Diversity Various diversity aspects such as race, ethnicity, socioeconomic status, digital literacy, distance to health care professional, mobility. 10 weeks
Primary Participant satisfaction Participant satisfaction measured using a questionnaire just after V2 (baseline), V6 and V9 (EOT) 6 months
Primary Site staff satisfaction Site staff satisfaction measured using a questionnaire (after study initiation visit [SIV]), after 3 enrolled participants, after 3 participants completed Week 12 and after last patient last visit (LPLV). 6 months
Primary Study cost Absolute cost per participant using a combination of prospective and retrospective measurements complete trial duration
Primary Time of AE (Adverse Event)/ SAE (Serious Adverse Event) occurence to collection Time from event occurrence to collection AE/SAE in the eDiary or eCRF (electronic Case Report Form), whichever is applicable. 6 months
Primary Treatment adherence Adherence to the daily insulin injection by means of eDiary analysis in percentage of days of documented intake until participant's EOT. 6 months
Primary Missing data Proportion of missing data on the critical data points (Hb1Ac, Fasting Glucose, Participant satisfaction questionnaire) 9 months
Primary Query rate Number of queries (both manual and automatic) per participant per arm. 9 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2

External Links